AstraZeneca's new project in Qingdao reaches milestone
The first phase of AstraZeneca's inhalation aerosol production and supply base in Qingdao was completed on April 24.
The facility, located in Qingdao National High-tech Industrial Development Zone and the first multinational pharmaceutical manufacturing project in Shandong province, has a total investment of $750 million and covers an area of 80 mu (5.33 hectares).
It will serve as an intelligent, high-capacity, and comprehensive inhalation aerosol production and supply base, aiming to achieve a zero-carbon factory status. The facility is expected to produce 54 million units of respiratory drugs annually for the Chinese market, injecting strong momentum into the Healthy China initiative.
Since the project broke ground in January 2024, Qingdao high-tech zone has provided comprehensive support throughout the construction process. Thanks to remarkable efficiency, the first phase is set for completion in 2028, while progress on the second phase and filling line expansion projects is progressing smoothly.
The AstraZeneca project not only fills a void in the multinational pharmaceutical manufacturing sector in Shandong province but also drives the comprehensive upgrade of the entire industry chain in areas such as respiratory disease diagnosis, treatment, and rare disease therapies through the simultaneous advancement of its regional headquarters, innovation center, and industrial fund projects.
In recent years, the Qingdao high-tech zone has led the construction of a modern industrial system through technological innovation. It has accelerated the development of a modern industrial system, with the core focus on the biopharmaceutical and medical device industry, supported by next-generation information technology and intelligent manufacturing and underpinned by modern services.
The first phase of AstraZeneca's inhalation aerosol production and supply base in Qingdao is completed on April 24. [Photo provided to chinadaily.com.cn]
The AstraZeneca project fills a void in the multinational pharmaceutical manufacturing sector in Shandong province. [Photo provided to chinadaily.com.cn]